Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial

Overview of attention for article published in Lancet Infectious Diseases, March 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

news: 2 news outlets

twitter: 47 X users

Readers on

mendeley: 41 Mendeley

So far, Altmetric has seen 49 X posts from 47 X users, with an upper bound of 288,413 followers.

RT @carl_jurassic: @Jikkyleaks @ThisNThatNews2 Correction He does list Q Pharma in one paper, but it’s not considered as a COI, I guess?…

@Jikkyleaks @ThisNThatNews2 Correction He does list Q Pharma in one paper, but it’s not considered as a COI, I guess? ZOMG -Look at the COIs of his coauthors though! https://t.co/TYnQUf2cbo rio mater https://t.co/x88L90rggi Q Pharm UQ, Mater but no CO…

RT @TheJikky: @FeeRedfern @John37866 Damn. Sarah Gilbert - the AZ lady. Patents. https://t.co/dcwjAyGdqj https://t.co/ZVDbY89PNf

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 45 additional X posts.